Kura Oncology, Inc. (KURA) has 6 SEC Form 4 insider filings on record in the last 90 days. That includes 2 insider purchases totalling $2.4M, and 3 sales totalling $1.3M. Most recent filing: Sept. 10, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 10, 2026 filed Sept. 8, 2026 | Fulk Jennifer Chief Financial Officer | $0 | 450,000 | 0% | Yes | |
|
|
||||||
| Aug. 24, 2026 filed Aug. 21, 2026 | Powl Brian T. Chief Commercial Officer | −$51,663 | 4,345 | −3% | Yes | |
|
|
||||||
| Aug. 24, 2026 | WILSON TROY EDWARD President and CEO | +$1,239,000 | 100,000 | +26% | No | |
|
|
||||||
| Aug. 21, 2026 filed Aug. 19, 2026 | Bair Teresa Brophy Chief Legal Officer | −$397,681 | 31,487 | −14% | Yes | |
|
|
||||||
| Aug. 17, 2026 | WILSON TROY EDWARD President and CEO | +$1,112,000 | 100,000 | +36% | No | |
|
|
||||||
Showing the 5 most recent of 6 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free